Experimental drug is first targeted therapy to improve survival in high-risk AML patients

Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Source link